Search results for "IMM"

showing 10 items of 18201 documents

Abstract CT156: A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunothera…

2018

Abstract Therapeutic vaccination with tumor antigen-encoding RNAs is being investigated in various clinical trials. Typically, the RNA vaccine is administered intradermally, subcutaneously or intranodally with the intention to get expression of the encoded antigens in local antigen-presenting cells (APCs). We have developed a novel class of RNA-lipoplex (RNA(LIP)) immunotherapeutics for intravenous application, which allow systemic targeting of APCs. RNA(LIP) is a novel nanoparticulate formulation of lipid-complexed mRNA which selectively delivers the functional mRNA to APCs in lymphoid compartments body-wide for efficient mRNA uptake and expression of the encoded antigen by APCs. Moreover,…

0301 basic medicineCancer Researchbusiness.industrymedicine.medical_treatmentMelanomaImmunogenicityImmunotherapymedicine.diseaseVaccination03 medical and health sciences030104 developmental biology0302 clinical medicineImmune systemOncologyAntigen030220 oncology & carcinogenesisImmunologyMedicineCancer vaccinebusinessAdjuvantCancer Research
researchProduct

Association ofStreptococcus gallolyticussubspeciesgallolyticuswith colorectal cancer: Serological evidence

2015

The colonic opportunist Streptococcus gallolyticus subspecies gallolyticus (SGG) is potentially associated with colorectal cancer (CRC). Large-scale seroepidemiological data for SGG antibodies and their possible association with CRC is currently missing. Associations between CRC and antibody responses to SGG were examined in 576 CRC cases and 576 controls matched by sex, age and province from a population-based multicase-control project (MCC-Spain). MCC-Spain was conducted between 2008 and 2013 in 12 Spanish provinces. Antibody responses to recombinant affinity-purified SGG pilus proteins Gallo1569, 2039, 2178 and 2179 were analysed by multiplex serology. Polyomavirus (PyV) JC VP1 and PyV 6…

0301 basic medicineCancer Researcheducation.field_of_studybiologyColorectal cancerPopulationmedicine.diseaseVirologyPilusSerologyPathogenesis03 medical and health sciences030104 developmental biologyOncologyAntigenImmunologybiology.proteinmedicineStreptococcus gallolyticusAntibodyeducationInternational Journal of Cancer
researchProduct

Genetic variations in the PSMA6 and PSMC6 proteasome genes are associated with multiple sclerosis and response to interferon‑β therapy in Latvians

2021

Several polymorphisms in genes related to the ubiquitin-proteasome system exhibit an association with pathogenesis and prognosis of various human autoimmune diseases. Our previous study reported the association between multiple sclerosis (MS) and the PSMA3-rs2348071 polymorphism in the Latvian population. The current study aimed to evaluate the PSMA6 and PSMC6 genetic variations, their interaction between each other and with the rs2348071, on the susceptibility to MS risk and response to therapy in the Latvian population. PSMA6-rs2277460, -rs1048990 and PSMC6-rs2295826, -rs2295827 were genotyped in the MS case/control study and analysed in terms of genotype-protein correlation network. The …

0301 basic medicineCancer Researcheducation.field_of_studybusiness.industryMultiple sclerosisHaplotypePopulationPSMA6Single-nucleotide polymorphismGeneral MedicineDiseasePSMA3medicine.diseasePSMC603 medical and health sciences030104 developmental biology0302 clinical medicineImmunology and Microbiology (miscellaneous)030220 oncology & carcinogenesisImmunologyMedicinebusinesseducationExperimental and Therapeutic Medicine
researchProduct

Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets

2019

Uveal Melanoma (UM) represents the most common primary intraocular malignant tumor in adults. Although it originates from melanocytes as cutaneous melanoma, it shows significant clinical and biological differences with the latter, including high resistance to immune therapy. Indeed, UM can evade immune surveillance via multiple mechanisms, such as the expression of inhibitory checkpoints (e.g., PD-L1, CD47, CD200) and the production of IDO-1 and soluble FasL, among others. More in-depth understanding of these mechanisms will suggest potential targets for the design of novel and more effective management strategies for UM patients.

0301 basic medicineCancer Researchimmune-escapemedicine.medical_treatmentReviewlcsh:RC254-282Fas ligand03 medical and health sciences0302 clinical medicineImmune privilegemedicinebusiness.industryMelanomaCD47Effective managementImmunotherapyinhibitory checkpointimmune-privilegemedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensImmune surveillanceimmune-escape; immune-privilege; immunotherapy; inhibitory checkpoints; uveal melanomainhibitory checkpoints030104 developmental biologyOncology030220 oncology & carcinogenesisCutaneous melanomaCancer researchimmunotherapyuveal melanomabusiness
researchProduct

High numbers of circulating CD57+ NK cells associate with resistance to HER2-specific therapeutic antibodies in HER2+ primary breast cancer.

2019

Abstract Natural killer (NK) cells can orchestrate effective antitumor immunity. The presence of tumor-infiltrating NK cells in diagnostic biopsies predicts pathologic complete response (pCR) to HER2-specific therapeutic antibodies in patients with primary breast cancer. Here, we analyzed whether diversity in circulating NK cells might influence tumor infiltration and HER2-specific therapeutic antibody efficacy. We found that numbers of circulating CD57+ NK cells inversely correlated with pCR to HER2-specific antibody treatment in patients with primary breast cancer independently of age, traditional clinicopathologic factors, and CD16A 158F/V genotype. This association was uncoupled from th…

0301 basic medicineCancer Researchmedicine.diagnostic_testbiologybusiness.industryImmunologymedicine.diseaseCXCR303 medical and health sciences030104 developmental biology0302 clinical medicineImmunophenotypingBreast cancer030220 oncology & carcinogenesisBiopsymedicineCancer researchbiology.proteinNeoplasmAntibodyskin and connective tissue diseasesReceptorbusinessHoming (hematopoietic)
researchProduct

Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities

2019

The oleogum resins of Boswellia species known as frankincense have been used for ages in traditional medicine in India, China and the Arabian world independent of its use for cultural and religious rituals in Europe. During the past two decades, scientific investigations provided mounting evidence for the therapeutic potential of frankincense. We conducted a systematic review on the anti-inflammatory and anti-cancer activities of Boswellia species and their chemical ingredients (e.g. 3-O-acetyl-11-keto-β boswellic acid, α- and β-boswellic acids, 11-keto-β-boswellic acid and other boswellic acids, lupeolic acids, incensole, cembrenes, triterpenediol, tirucallic acids, and olibanumols). Frank…

0301 basic medicineCancer Researchmedicine.drug_classAnti-Inflammatory AgentsPharmacologyAnti-inflammatory03 medical and health scienceschemistry.chemical_compound0302 clinical medicineImmune systemPsoriasismedicineHumansImmunologic FactorsBoswelliaAdverse effectBoswelliabiologybusiness.industryCancerGliomaFrankincenseFrankincensemedicine.diseasebiology.organism_classification030104 developmental biologychemistry030220 oncology & carcinogenesisBoswellic acidbusinessResins PlantSeminars in Cancer Biology
researchProduct

Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer

2021

Simple Summary The immune checkpoint blockade (ICB), and concretely the blockade of the PD1/PDL1 axis, has opened up a new standard of treatment for non-small cell lung cancer (NSCLC). However, despite substantial advances in clinical care, many patients still remain refractory to these therapies. Biomarkers such as PD-L1 expression and tumor mutational burden have been associated with ICB efficacy, but the mechanisms underlying variable responses are not yet fully understood. Recently, the differential composition of the gut microbiota was studied as one of the variables accounting for interpatient heterogeneity in ICB responses. To better understand the potential role of the gut microbiot…

0301 basic medicineCancer Researchmedicine.drug_classmedicine.medical_treatmentAntibioticsGut floradigestive systemArticle03 medical and health sciences0302 clinical medicinemedicineLung cancerRC254-282non-small cell lung cancerbiologygut microbiotabusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmunotherapyimmune checkpoint blockademedicine.diseasebiology.organism_classificationImmune checkpointBlockade030104 developmental biologyOncology030220 oncology & carcinogenesisImmunologyBiomarker (medicine)biomarkernext-generation sequencingimmunotherapybusinessProgressive disease
researchProduct

Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment.

2019

Background: Patients with refractory or relapsed diffuse large B-cell lymphoma have a poor prognosis with the current standard of care. Objective: Chimeric Antigen Receptor T-cells (CAR T-cells) are functionally reprogrammed lymphocytes, which are able to recognize and kill tumor cells. The aim of this study is to make progress in this area. Method: A mini-review was achieved using the articles published in Web of Science and PubMed in the last year and the new patents were made in this field. Results: The responses to CAR T-cell products axicabtagene ciloleucel and tisagenlecleucel are promising; the objective response rate can reach up to 83%, and the complete response rate ranges betwee…

0301 basic medicineCancer Researchmedicine.drug_classmedicine.medical_treatmentT-LymphocytesMonoclonal antibodyImmunotherapy Adoptive03 medical and health sciences0302 clinical medicineInterferonDrug DiscoveryMedicineHumansPharmacology (medical)Clinical Trials as TopicReceptors Chimeric Antigenbusiness.industryGeneral MedicineImmunotherapymedicine.diseaseFusion proteinChimeric antigen receptorLymphomaCytokine release syndrome030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchLymphoma Large B-Cell DiffusebusinessDiffuse large B-cell lymphomamedicine.drugRecent patents on anti-cancer drug discovery
researchProduct

Acute surgical abdomen during the COVID‑19 pandemic: Clinical and therapeutic challenges

2021

The present study investigated the effects of the COVID-19 pandemic on the clinical presentation and therapeutic management of acute surgical abdomen. A retrospective study of emergency hospitalizations with a diagnosis of acute surgical abdomen between April and July 2020 vs. a similar period in 2019 was performed. The observation sheets and the operating protocols were analyzed. Between April and July 2020, 50 cases of acute surgical abdomen were hospitalized and treated, compared to 43 cases in the same period last year. The main types of pathology in both groups included: Occlusions (60%, respectively 44.2% in 2019) and peritonitis (32%, respectively 41.8% in 2019). There was an increas…

0301 basic medicineCancer Researchmedicine.medical_specialtyAbdominal painbusiness.industryGeneral surgeryPerforation (oil well)PeritonitisRetrospective cohort studyArticlesGeneral Medicinemedicine.diseaseAsepsis03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureImmunology and Microbiology (miscellaneous)Acute abdomen030220 oncology & carcinogenesisPandemicmedicineAbdomenmedicine.symptombusinessExperimental and Therapeutic Medicine
researchProduct

Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions

2019

Purpose: Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine carcinoma arising from the skin. We aimed to review and deal with some of the most relevant controversial topics on the correct use of immunotherapy for the treatment of MCC. Methods: The primary search was carried out via PubMed, EMBASE, and the Cochrane Library (until 31st May, 2018), while other articles and guidelines were retrieved from related papers or those referenced in these papers. Additionally, we performed an extensive search on ClinicalTrials.gov to gather information on the ongoing clinical trials related to this specific topic. Results: We performed an up-to-date critical review taking into account the…

0301 basic medicineCancer Researchmedicine.medical_specialtyAvelumabSkin NeoplasmsPrognosimedicine.medical_treatmentPembrolizumabImmune checkpoint inhibitorCochrane LibraryB7-H1 AntigenSettore MED/13 - EndocrinologiaAvelumab03 medical and health sciencesImmune checkpoint inhibitors0302 clinical medicineMerkel cell carcinomaNeuroendocrine tumoursNeuroendocrine tumourmedicineAnimalsHumansSkin NeoplasmIntensive care medicineMerkel cell carcinomabusiness.industryAnimalAntibodies MonoclonalGeneral MedicineImmunotherapymedicine.diseasePrognosisImmune checkpointBlockadeClinical trialCarcinoma Merkel Cell030104 developmental biologyOncology030220 oncology & carcinogenesisImmunotherapyTherapyAvelumab; Immune checkpoint inhibitors; Merkel cell carcinoma; Neuroendocrine tumours; Pembrolizumab; TherapybusinessPembrolizumabmedicine.drugHuman
researchProduct